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Cardiovascular diseases are still the
leading cause of death worldwide.
Impaired endothelial function followed
by inﬂammation of the vessel wall leads
to atherosclerotic lesion formation that
causes myocardial infarction and stroke.
The increase of major risk factors such
as obesity and diabetes in industrialized
but also developing countries further
increases the burden of vascular disease.
Heart failure can occur as consequence
of large myocardial infarctions or can
be caused by genetic predisposition or
infectious disease. In its more severe
stages, heart failure patients have a life
expectancy that is similar to aggressive
cancers. Due to the rising age of the
population, the incidence of heart failure
is further increasing. Thus, the increase
in risk factor load by metabolic diseases
and age augments the incidence for
vascular and cardiac diseases and pro-
vides a challenge for developing efﬁcient
treatments.
The goal of this thematic review series
is to highlight some emerging ﬁelds in
cardiovascular research and translation.
» The goal of this thematic
review series is to highlight
some emerging fields in
cardiovascular research and
translation.«
Targeting Chemokines: Despite
improved pharmacological and interven-
tional therapies, a causative treatment
of atherosclerosis is missing. It is well
known that vascular inﬂammation plays
a key role in the pathogenesis of athero-
sclerosis and modulating this inﬂamma-
tory reaction may interfere with this
chronic disease. Chemokines comprise
one group of the regulators of inﬂamma-
tion by directing the movement and
activity of leukocytes. The review article
by Christian Weber and Rory Koenen
(University Munich) will summarize the
pathophysiological role and the chal-
lenges in targeting chemokines for ther-
apy of atherosclerosis.
Targeting HDL: The pharmacological
lowering of low-density lipoproteins, the
‘bad’ cholesterol, for example by HMG-
CoA reductase inhibitors (‘statins’),
enabled the successful treatment of
hypercholesterolemia and signiﬁcantly
reduced coronary artery disease. How-
ever, despite ample evidence for a pro-
tective function of high-density lipopro-
tein (HDL), attempts to increase this
protective lipoprotein failed to protect
against atherosclerotic disease in patients.
Currently, it is unclear why strategies to
elevate HDL failed. One hypothesis is that
HDL is modiﬁed in patients with coronary
artery disease, thereby, losing its protec-
tive function. Ulf Landmesser, Christian
Besler and Thomas Lu ¨scher (University
Zu ¨rich) will discuss the current state and
future of using HDL as a therapeutic
protective target for the treatment of
coronary artery disease.
Targeting MicroRNA: MicroRNAs are
small non-coding RNAs that post-tran-
scriptionally control gene expression by
inducing RNA degradation or inhibiting
protein translation. MicroRNAs play a
crucial role in tissue homeostasis and
disease and gained increasing interest as
biomarkers for various diseases. Several
studies meanwhile also provide evidence
that microRNAs are therapeutic targets
and that inhibition of microRNAs can
ameliorate cardiovascular diseases in
experimental models. Thomas Thum,
Hannover, will discuss the role of micro-
RNAs in cardiovascular diseases.
Targeting Regeneration: One of the
most promising options for treating heart
failure is to generate cardiomyocytes.
Stem cell-based approaches may help to
maintain organ function by replacing
damaged or lost cells. Some tissues
including the heart harbour stem/pro-
genitor cells that to some extent may
contribute to regeneration. However, in
disease conditions, the endogenous
repair capacity of the heart is not
sufﬁcient and either transplantation of
cells or further activation of endogenous
cells might provide a therapeutic option.
The possibility to stimulate the replace-
ment of cardiomyocytes by activating
endogenous repair (including endogen-
ous stem cells) and by reprogramming
cells within the heart will be discussed by
Richard Lee and Matthew Steinhauser
(Harvard).
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